# Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

> **NCT07096063** · — · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 887132 (actual)

## Conditions studied

- Type 2 Diabetes
- Overweight
- Cardiovascular (CV) Risk

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Dulaglutide
- **DRUG:** Semaglutide
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT07096063
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-01
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 887132 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07096063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07096063, "Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07096063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*